Navamedic ASA ( (DE:N1A) ) has shared an announcement.
Navamedic ASA announced that the European Medicines Agency’s human medicines committee has affirmed the benefits of Mysimba, a weight management medicine, outweigh its risks, with no cardiovascular safety concerns for up to 12 months of use. The ongoing INFORMUS safety study will provide long-term insights, and Navamedic is committed to ensuring Mysimba’s safety and efficacy while working closely with healthcare providers to keep them informed of updated guidelines.
More about Navamedic ASA
Navamedic ASA is a Nordic pharmaceutical company focused on improving quality of life by supplying high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. The company addresses public health concerns such as obesity, Parkinson’s disease, and gastro-related ailments and is known for its local insight and competence in the Nordics and Benelux regions. Navamedic is listed on the Oslo Stock Exchange and is headquartered in Oslo, Norway.
YTD Price Performance: -11.08%
Technical Sentiment Signal: Buy
Current Market Cap: €33.86M
See more insights into N1A stock on TipRanks’ Stock Analysis page.